Live Breaking News & Updates on Rare Genetics

Stay updated with breaking news from Rare genetics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda Showcases Digital Health Solutions at G20 Meeting in India

Takeda Showcases Digital Health Solutions at G20 Meeting in India : Rashtra News Takeda Biopharmaceuticals India Private Limited Showcased Digital Innovations - MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting The Three-Day Meeting was Held in Goa, India, from April 17th to April 19th, 2023, and Side Event was Focused on: ‘Citizen-Centric ....

Ruchi Sogarwal , Mansukh Mandaviya , Puneet Chopra , Gabriele Ricci , Serina Fischer , Takeda Showcases Digital Health Solutions , Takeda Biopharmaceuticals India Private , Takeda Biopharmaceutical India Pvt Ltd , Health Working Group , Digital Health , Takeda Pharmaceutical Company , Honble Union Health , Head Of Corporate Affairs , Health Working Group Meeting , Working Group , Three Day Meeting , Side Event , Citizen Centric Health Delivery Ecosystems , Biopharmaceuticals India Private Limited , Baxalta Bioscience India , Hon Ble Union Health Minister , Anaplastic Lymphoma Kinase Positive , Non Small Cell Lung Cancer , Universal Health Coverage , General Manager , Takeda Biopharmaceutical India ,

Takeda Enters Into Two-Year Contract with Canadian Blood Services for GLASSIA®, Treatment for Rare form of Emphysema - Takeda Pharmaceutical (NYSE:TAK)

Availability of GLASSIA® represents significant milestone for patients with emphysema due to severe hereditary deficiency of Alpha-1 antitrypsin TORONTO, Dec. 20, 2023 /CNW/ - Takeda Canada Inc. (Takeda) has ....

Angela Diano , Ken Chapman , Canadian Blood Services , Health Canada , Takeda Pharmaceutical Company Limited , Takeda Canada Inc , University Health Network , University Of Toronto , Asthma Airway Centre , Takeda Canada , Related Products , Airway Centre , Executive Director , Proteinase Inhibitor , Rute Fernandes , General Manager , Rare Genetics , Plasma Derived Therapies ,

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology

Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting. ....

San Diego , United States , John Cunningham , Awny Farajallah , German Hodgkin Study Group , European Union , Takeda Pharmaceutical Company Limited , Takeda Pharmaceuticals , Health Canada , Drug Administration , Takeda Pharmaceuticals United Statesa Inc , Exchange Commission , Important Safety Information European Union , Japan Ministry Of Health , European Medicines Agency , Takeda Pharmaceuticals International , American Society Of Hematology , American Society , Annual Meeting , Rare Genetics , Orphan Drug Designation , Fast Track , Rare Pediatric Disease , Rare Pediatric Disease Priority Review Voucher , Specific Populations , Takeda Pharmaceuticals United Statesa ,

New Campaign Celebrates Canadian Rare Disease Changemakers

/CNW/ - Today, 13 Canadian rare disease organizations, in partnership with Takeda Canada Inc. ("Takeda",) unite to launch I Am Number 12, to raise awareness of. ....

United States , Kelly Newell , Emilita Dela Cruz , Aneal Khan , Christine White , Elisabeth Linton , Canadian Organization For Rare Disorders , Foundation Of Canada , Association Des Patients Immunod , Takeda Pharmaceutical Company Limited , Takeda Canada Inc , National Gaucher Foundation Of Canada , Canadian Fabry Association , Sickle Cell Disease Association Of Canada , National Strategy For Drugs , Takeda Canada , Sanfilippo Syndrome , Kerstyn Lane , Hereditary Angioedema Type , Vice President , Regional Director , National Strategy , Rare Diseases , National Gaucher Foundation , Rute Fernandes , General Manager ,

The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)

/PRNewswire/ Takeda (TSE:4502/NYSE:TAK) today announced the European Commission has approved TAKHZYRO® (lanadelumab) for the routine prevention of recurrent. ....

United Kingdom , United States , Didier Relin , Prnewswire Takeda , European Commission , European Medicines Agency , Takeda Pharmaceutical Company Limited , Drug Administration , Takeda Pharmaceutical Company , Head Of International Regulatory At Takeda , European Commission Decision , First Routine Prevention Treatment , Patients Under , New Preventative Treatment Option , Hereditary Angioedema , European Economic Area , Adolescent Study , Biologics License Application , International Regulatory , Commission Decision , Open Label Phase , Evaluate Safety , Prevention Against Acute Attacks , Pediatric Patients , About Takeda Pharmaceutical , Rare Genetics ,